NYSE:KAPA
Kairos Pharma, LTD.
Kairos Pharma, LTD. reported net income of −$5.4M in fiscal 2025. The diluted share count rose 62.3%.Summary generated from Kairos Pharma, LTD.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−98.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+62.3%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −2 | −2 | −6 |
| Net income | −2 | −3 | −5 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Oct 6, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 8-KAmendment to articles or bylaws
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KEntry into a material agreement
Jul 22, 2026 - 8-KOther events
Jul 15, 2026 - 8-KResults of a shareholder vote
Jun 30, 2026 - 8-KOther events
Jun 4, 2026